Clinical implications of statin therapy in patients undergoing hemodialysis

American Journal of Health-System Pharmacy

Volumn 71, Issue 9, 2014, Pages 703-710

  Kim, Jenny J ^a   Langworthy, Diana R ^b   Hennessey, Erin K ^c  

^a SHENANDOAH UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG SAFETY; DYSLIPIDEMIA; END STAGE RENAL DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; META ANALYSIS; MULTICENTER STUDY (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; AGED; CARDIOVASCULAR DISEASES; COMPLICATION; KIDNEY FAILURE, CHRONIC; META ANALYSIS (TOPIC); MIDDLE AGED; RENAL REPLACEMENT THERAPY;

AGED; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; META-ANALYSIS AS TOPIC; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS;

EID: 84907206938     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp130305     Document Type: Article

References (24)

1. United States Renal Data System. USRDS 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. www.usrds.org/atlas12.aspx (accessed 2014 Jan 29).
2. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease. Circulation. 2003; 108:2154-69.
3. National Kidney Foundation. KDOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. www.kidney.org/professionals/Kdoqi/guidelines-lipids/index.htm (accessed 2014 Jan 29).
4. National Kidney Foundation. KDOQI clinical practice guidelines for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012; 60:850-86.
5. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. www.kdigo.org/clinical-practice-guidelines/Lipids/KDIGO%20Lipid%20Management%20Guideline%202013.pdf (accessed 2014 Jan 29).
6. Mason NA, Bailie GR, Satayathum S et al. HMG-coenzyme A reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis. 2005; 45:119-26.
7. Strippoli G, Navaneethan SD, Johnson DW et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008; 336:645-51.
8. Navaneethan SD, Nigwekar SU, Perkovic V et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2009; 3: CD004289.
9. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353:238-48.
10. Marz W, Genser B, Drechsler C et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol. 2011; 6:1316-25.
11. Food and Drug Administration. Drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease. www.fda.gov/Drugs/DrugSafety/ucm 259639.htm (accessed 2012 Nov 28).
12. Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003; 107:2920-5.
13. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22:983-8.
14. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med . 2009; 360: 1395-407.
15. Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377:2181-92.
16. Fried L, Hutchison A, Stegmayr B et al. Recommendations for the treatment of lipid disorders in patients on peritoneal dialysis. Perit Dial Int. 1999; 19:7-16.
17. Siamopoulos KC, Elisaf MS, Bairaktari HT et al. Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis. Perit Dial Int. 1995; 15:342-7.
18. Attman PO, Samuelsson OG, Moberly J et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int. 1999; 55:1536-42.
19. Johansson AC, Samuelsson O, Attman PO et al. Dyslipidemia in peritoneal dialysis-relation to dialytic variables. Perit Dial Int. 2000; 20:306-14.
20. Palmer SC, Craig JC, Navaneethan SD et al. Benefits and harms of statin therapy for persons with chronic kidney disease. Ann Intern Med. 2012; 157:263-75.
21. Hou W, Lv J, Perkovic V et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013; 34:1807-17.
22. Palmer SC, Navaneethan SD, Craig JC et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2013; 9:CD004289.
23. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361:2019-32.
24. United States Renal Data System. USRDS 2007 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. www.usrds.org/atlas07.aspx (accessed 2014 Jan 29).